The EORTC Genito-Urinary Tract Cancer Group: 25 years of achievements and future strategiesBONO, A; ZURLO, A.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 4, pp S71-S74, issn 1359-6349Article

Maintenance Bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: Results from a european organisation for research and treatment of cancer genito-urinary group phase III trialVAN DER MEIJDEN, Adrian P. M; SYLVESTER, Richard J; OOSTERLINCK, Wim et al.European urology. 2003, Vol 44, Num 4, pp 429-434, issn 0302-2838, 6 p.Article

The side effects of Bacillus Calmette-Guerin in thetreatment of TaT1 bladder cancer do not predict its efficacy: Results from a european organisation for research and treatment of cancer genito-urinary group phase III trialSYLVESTER, Richard J; VAN DER MEIJDEN, Adrian P. M; OOSTERLINCK, Wim et al.European urology. 2003, Vol 44, Num 4, pp 423-428, issn 0302-2838, 6 p.Article

An international field study of the EORTC QLQ-PR25 : A questionnaire for assessing the health-related quality of life of patients with prostate cancerVAN ANDEL, George; BOTTOMLEY, Andrew; D'HAESE, Suen et al.European journal of cancer (1990). 2008, Vol 44, Num 16, pp 2418-2424, issn 0959-8049, 7 p.Article

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)THEODORE, C; SKONECZNA, I; BODROGI, I et al.Annals of oncology. 2008, Vol 19, Num 7, pp 1304-1307, issn 0923-7534, 4 p.Article

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the BladderSYLVESTER, Richard J; BRAUSI, Maurizio A; DE REIJKE, Theo M et al.European urology. 2010, Vol 57, Num 5, pp 766-773, issn 0302-2838, 8 p.Article